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lipidsBackground/Purpose: Aggressive and persistent control of risk factors is recommended for pre-
vention of secondary comorbidities in patients with cardiovascular diseases. This study aimed
to evaluate guideline recommendations for achieving targets for lipid and blood pressure (BP)
control in patients with cardiovascular diseases in Taiwan.
Methods: This multicenter cohort study was conducted in 14 hospitals in Taiwan. A total of
3316 outpatients who had established cerebrovascular disease (CVD), coronary artery disease
(CAD), or both were recruited. Risk factors for comorbid conditions such as high BP, sugar, he-
moglobin A1C, abnormal lipids, lipoproteins, and medication use were compared between pa-
tients with CVD, CAD, or both.
Results: Of all patients, 503 (15.2%) had CVD only, 2568 (77.4%) had CAD only, and 245 (7.4%)
had both CVD and CAD. Compared with patients who had only CAD, those with CVD were older,
had higher frequency of hypertension, and lower frequency of diabetes mellitus. Patients with
CAD were more likely to receive lipid-lowering and antihypertensive drugs than those with CVD
(p < 0.001). Only 54.8% and 55.9% of patients achieved the recommended lipid and BP control
targets, respectively. Patients with CVD (adjusted odds ratio: 0.61; 95% confidence interval:
0.48e0.78; p < 0.001) and women (adjusted odds ratio: 0.65; 95% confidence interval: 0.55
e0.78; p < 0.001) were less likely to achieve the recommended lipid and BP targets.
Conclusion: The guideline-recommended targets for lipids and BP in patients with CAD and CVD
were still suboptimal in Taiwan. Greater efforts are required to achieve the targets, particu-
larly in patients with CVD and in women.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
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Cardiovascular disease, including both coronary artery
disease (CAD) and cerebrovascular disease (CVD), accounts
for nearly half of all noncommunicable diseases and is the
world’s major disease burden. It is the leading cause of
global mortality and results in 17.3 million deaths every
year, a number that is expected to grow to 23.6 million or
24% by 2030.1 Cardiovascular mortality has been declining
slowly, particularly in high-income countries, an outcome
that can probably be attributed to risk factor reduction in
recent decades.2,3 A global target to reduce premature
noncommunicative disease mortality by 25% before 2025
has been proposed by the World Health Organization. The
Global Cardiovascular Disease Taskforce endorses some
exposure targets on physical inactivity, hypertension, di-
etary salt intake, tobacco, obesity, and raised cholesterol
as those required to achieve the goal.4
Of the numerous cardiovascular risk factors, both hy-
pertension and dyslipidemia are commonly encountered
and relatively easily modifiable; in addition, antihyperten-
sive and lipid-lowering therapies have well-established
benefits in the primary and secondary prevention.5e7 A
nationwide follow-up of ischemic stroke patients revealed
that treatment with antiplatelets, oral anticoagulants,
antihypertensives, and statins can improve secondary pre-
vention in routine care.8 However, hypertension and dysli-
pidemia are often undertreated, and established therapies,
including antiplatelets, statins, antihypertensive agents,
are consistently underused in atherothrombotic patients
worldwide.9 In the international REduction of Athero-
thrombosis for Continued Health (REACH) Registry Europe,
less than 60% of patients with stable atherothrombotic
diseases had good control of the following five major car-
diovascular risk factors: systolic blood pressure (BP)<140 mmHg, diastolic BP <90 mmHg, fasting glycemia
<110 mg/dL, total cholesterol <200 mg/dL, and
nonsmoking.10
Among the cardiovascular disease patients, patients
with CVD were probably more likely not to receive antihy-
pertensive, lipid-lowering, and antiplatelet therapies than
those with CAD.11e14 The guideline-recommended treat-
ment targets were also less likely to be achieved in CVD
patients than in CAD patients. In the Taiwan Stroke Regis-
try, only 38.7% of acute ischemic stroke patients with low-
density lipoprotein cholesterol (LDL-C) 100 mg/dL
received lipid-lowering drugs before discharge.15 In addi-
tion, women with cardiovascular diseases were reported to
be less likely to receive antihypertensives, antiplatelets,
and statins than men.12,16,17 This study aimed to evaluate
to what extent the guideline-recommended targets for
several comorbid conditions are achieved in patients with
CVD and/or CAD selected from a multicenter registry.
Patients and methods
Study population
This study was conducted from a multicenter observational
registry, the Taiwanese Secondary Prevention for patients
with AtheRosCLErotic disease (T-SPARCLE) Registry, from 14
teaching hospitals in Taiwan.18 This registry attempts to
recruit and follow-up a large population of patients with
cardiovascular diseases who have been receiving secondary
prevention therapies so as to define the current status of
these therapies and their effects on morbidity and mor-
tality in Taiwan.
Adultpatientswhohadstable symptomaticatherosclerotic
diseases, including CAD and CVD, were recruited. Patients
with CAD were defined as those who had significant coronary
1002 J.-S. Jeng et al.artery stenosis (>50%), or had a history of myocardial infarc-
tion, or who had angina showing ischemic electrocardio-
graphic changes or positive response to stress tests. Patents
with CVD were defined as those with cerebral infarction,
intracerebral hemorrhage, and transient ischemic attack
attributed to cervical or intracranial large artery stenosis
(>50%). The study was approved by the Institutional Review
Board of each participating hospital, and written informed
consent was obtained from all patients.
Targets measurement
Eligible patients who fulfilled the enrollment criteria and
agreed to participate in the study will be followed up every
year for a total of 5 years. At every visit, vital signs, body
mass index, lifestyle (smoking and drinking habits, physical
activity), clinical end points, adverse events, information
on concurrent medications, and blood test results,
including lipid profile [total cholesterol, high-density lipo-
protein cholesterol (HDL-C), triglyceride], complete blood
cell counts, fasting glucose, hemoglobin A1C, liver enzymes,
creatinine, and creatine kinase were obtained as thor-
oughly as possible.
The concurrent medications and their dosage were
recorded in detail, including antiplatelets (i.e., aspirin,
clopidogrel, dipyridamole, aspirin þ high-dose dipyr-
idamole, cilostazol), oral anticoagulant, antihypertensive
agents (i.e., calcium-channel blockers, b-blockers, a-
blocker, diuretics, angiotensin-converting enzyme in-
hibitors, angiotensin receptor blockers), antidiabetic
agents (oral hypoglycemic agents and insulin), and lipid-
lowering drugs (e.g., statin, fibrate, Ezetimibe, bile acid
sequestrants, nicotinic acid). The guideline-recommended
lipid and BP targets were applied for evaluation of the
achievement. The optimal lipid level was LDL-C
<2.6 mmol/L (100 mg/dL) and the optimal BP was <140/
90 mmHg for nondiabetic patients and <130/80 mmHg for
diabetic patients.
Statistical analysis
Categorical variables are presented as percentage, and
continuous or discrete variables as mean  standard devi-
ation. The risk factor conditions, including BP, fasting
sugar, lipids and lipoproteins, and medication use,
including antihypertensive, antidiabetic, lipid-lowering,
and antithrombotic drugs were compared between pa-
tients with CVD, CAD, and patients who had both CVD and
CAD. The c2 test was used to compare proportions; the
Student t test or analysis of variance was applied to
compare differences in continuous variables between
groups. A logistic regression analysis was adapted to eval-
uate the odds ratio and 95% confidence intervals of the
recommended lipid and BP control targets. Statistical an-
alyses were performed using the SPSS software package
(version 17.0; SPSS Inc, Chicago, IL, USA).
Results
From January 2010 to February 2011, 3316 patients
(men: 72.3%; mean age: 66.7  11.6 years) wereincluded in this analysis. Of these, 503 (15.2%) had CVD
only, 2568 (77.4%) had CAD only, and 245 (7.4%) had
both CVD and CAD. Of the 748 patients with CVD (alone
or co-existing CAD), 94 patients had a history of hem-
orrhagic stroke. About two-thirds of patients were
recruited 2 years and more after their first vascular
event. The demographics and clinical characteristics of
the patients, and a comparison of these variables among
the three groups of cardiovascular diseases are shown in
Table 1. Compared with patients with CAD only, those
with CVD were older, had higher frequency of hyper-
tension, and lower frequencies of males, diabetes mel-
litus, and physical inactivity. Patients with CVD alone or
co-existing CAD had higher systolic and diastolic BP than
those with CAD alone (p < 0.001). The serum levels of
total cholesterol, HDL-C, and LDL-C were significantly
higher in patients with CVD alone than in those with CAD
alone or co-existing CVD. By contrast, CAD patients had
higher serum levels of fasting sugar, creatinine, and
creatine kinase than did CVD patients.
Table 2 shows the prescription status of therapies for
prevention of secondary comorbidities in patients with CVD
and/or CAD. Antihypertensive agents were less likely to be
administered in patients with CVD only than in other pa-
tients. About one half of patients received calcium-channel
blockers, b-blockers, or angiotensin receptor blockers. The
b-blockers and angiotensin-converting enzyme inhibitors
were more likely to be used in patients with CAD than in
those with CVD. The antidiabetic prescription rate was
higher in patients with CAD than in patients with CVD,
which may be related to a higher prevalence of diabetes
mellitus. Patients with CVD only were significantly less
likely to take lipid-lowering drugs, particularly statins, than
those with CAD only (42.1% vs. 79.8%, p < 0.001). After
excluding patients with a history of hemorrhagic stroke,
antithrombotic agents were still less likely to be used in
patients with CVD only than in those with CAD. Patients
with CVD only were less commonly taking aspirin and clo-
pidogrel, but more commonly taking aspirin plus extended
release dipyridamole and ticlopidine than were those with
CAD.
Overall, 54.8% and 55.9% of patients can achieve
guideline-recommended targets of LDL-C (<2.6 mmol/L)
and BP (<140/90 mmHg for nondiabetic patients and <130/
80 mmHg for diabetic patients, respectively). Only 31.2% of
patients achieved both LDL-C and BP targets. Patients with
CVD only were less likely to achieve the BP and LDL-C tar-
gets than those with CAD, especially in achieving the LDL-C
target. A sex difference was observed in BP target
achievement among CVD and/or CAD patients and in lipid
target achievement for CAD patients. Women were less
likely to meet the recommended targets than were men
(Fig. 1).
Results of multivariate logistic regression analysis of
variables associated with separate or both lipid and BP
target achievements are presented in Table 3. Compared
with patients with CAD only, those with CVD only, and pa-
tients with co-existing CVD and CAD were less likely to
achieve the guideline-recommended lipid and BP targets.
Women were also less likely to meet the BP and lipid tar-
gets, and diabetic patients had opposite effects on lipid
and BP target achievement.
Table 1 Demographics and clinical characteristics of the study patients.
Overall (n Z 3316) CVD only (n Z 503) CAD only (n Z 2568) CVD þ CAD (n Z 245) p
Age (y) 66.7  11.6 68.5  11.6 65.9  11.6 70.7  10.6 <0.001
Men 2399 (72.3) 320 (63.6) 1911 (74.4) 168 (68.6) <0.001
Body mass index (kg/m2) 26.1  3.8 25.6  3.4 26.2  3.7 25.6  4.3 <0.001
Waist-to-hip ratio 0.93  0.07 0.92  0.07 0.93  0.07 0.94  0.07 0.008
Hypertension 2485 (74.9) 423 (84.1) 1856 (72.3) 206 (84.1) <0.001
Diabetes 1389 (41.9) 178 (35.4) 1088 (42.4) 123 (50.2) <0.001
Heart failure 286 (8.6) 27 (5.4) 228 (8.9) 31 (12.7) 0.002
Smoking habit
Current 473 (14.3) 68 (13.5) 376 (14.6) 29 (11.8) 0.435
Former 858 (25.9) 119 (23.7) 675 (26.3) 64 (26.1) d
Never 1985 (59.9) 316 (62.8) 1517 (59.1) 152 (62.0) d
Drinking habita 586 (13.0) 51 (10.1) 398 (15.5) 17 (6.9) <0.001
Physical inactivityb 1788 (53.9) 230 (45.7) 1437 (56.0) 121 (49.4) <0.001
Time since vascular event
2 y 1097 (36.2) 137 (33.3) 925 (38.8) 35 (15.0) <0.001
>2 y 1934 (63.8) 274 (66.7) 1462 (61.2) 198 (85.0) d
Systolic BP (mmHg) 133.1  17.6 134.8  16.6 132.3  17.3 137.7  21.0 <0.001
Diastolic BP (mmHg) 76.1  11.3 78.2  11.2 75.5  11.2 77.6  11.8 <0.001
Heart rate (bpm) 74.6  12.9 73.0  14.8 74.9  12.5 75.3  13.7 0.031
TC (mg/dL) 173.2  40.3 184.3  38.9 171.2  40.1 172.1  40.5 <0.001
TG (mg/dL) 143.1  96.1 140.6  80.5 144.6  101.4 132.7  64.4 0.169
HDL-C (mg/dL) 44.9  13.1 46.4  13.7 44.5  12.9 45.5  13.6 0.020
LDL-C (mg/dL) 99.6  33.2 106.4  33.7 98.2  33.0 100.0  33.0 <0.001
TC-to-HDL-C ratio 4.1  1.5 4.2  1.4 4.1  1.4 4.2  2.3 0.176
Fasting glucose (mg/dL) 120.0  41.2 114.5  33.5 120.6  41.9 123.2  45.2 0.018
Hemoglobin A1C (%) 7.1  1.4 7.1  1.4 7.1  1.5 7.2  1.3 0.822
Creatinine (mg/dL) 1.2  0.9 1.1  0.6 1.2  0.9 1.5  1.4 <0.001
Creatine kinase (mg/dL) 129.1  156.5 94.0  73.1 134.3  165.3 104.4  95.1 0.018
AST (mg/dL) 29.4  18.0 27.5  17.8 29.5  17.3 31.1  24.0 0.197
ALT (mg/dL) 29.1  20.3 26.7  22.2 29.6  20.0 27.2  19.5 0.045
Hemoglobin (g/dL) 13.6  1.8 13.4  1.9 13.7  1.8 13.0  2.0 <0.001
WBC count (103/mL) 7.2  2.3 7.4  2.2 7.1  2.3 7.3  2.3 0.363
Platelet count (103/mL) 211.1  60.8 227.6  71.7 208.9  58.6 204.2  58.4 <0.001
Values are number (percentage) or mean (standard deviation).
ALT Z alanine aminotransferase; AST Z aspirate aminotranferase; BP Z blood pressure; CAD Z coronary artery disease;
CVDZ cerebrovascular disease; HDL-CZ high-density lipoprotein cholesterol; LDL-CZ low-density lipoprotein cholesterol; TCZ total
cholesterol; TG Z triglyceride; WBC Z white blood cell.
a Indicating a habit of alcohol consumption at least once per month currently.
b Indicating no vigorous exercise corresponding to brisk walking >30 minutes each time currently.
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As in several previous observational studies,11e14 the pre-
sent study showed that secondary prevention therapies in
patients with atherosclerotic diseases were suboptimal in
the ethnic Chinese population in Taiwan. Only 54.8% and
55.9% of patients achieved lipid and BP targets, respec-
tively, and 31% achieved combined BP and lipid targets. It is
clearly recognized that patients with atherosclerotic dis-
eases are at an elevated risk for recurrent vascular events
and death, which can be diminished by intensive risk fac-
tors modification, including lifestyle amendment and sec-
ondary prevention therapy.19e21 However, there was a wide
gap between the guideline-recommendation, which is
mainly based on large randomized clinical trials and meta-
analysis, and the routine clinical practice. In a cross-sectional study among 7649 in-hospital CAD patients from
76 centers in 22 European regions, only half of CAD patients
achieved BP control, with emphasis on CAD patients with
obesity, diabetes, and dyslipidemia.22 In a cohort study of
12,830 stroke patients in England, only 25.6% of male and
20.8% of female patients received adequate secondary
prevention therapies.23 In the Vitamin Intervention for
Stroke Prevention trial, more than half of ischemic stroke
patients with LDL-C >100 mg/dL were not on statins.24 The
Lipid Treatment Assessment Project 2 showed that the
proportion of patients achieving appropriate LDL-C goals
for the patient’s level of risk ranged from 47% to 84% across
countries, with a level of 67% among the high-risk patients.
Moreover, among CAD patients with more than two risk
factors, only 30% attained the optional LDL-C goal of
<70 mg/dL.25
Table 2 Antihypertensive, lipid-lowering, antidiabetic, and antithrombotic treatment.
Overall
(n Z 3316)
CVD only
(n Z 502)
CAD only
(n Z 2568)
CVD þ CAD
(n Z 245)
p
Antihypertensive drugs
Current use 2867 (86.5) 387 (76.9) 2270 (88.4) 210 (85.7) <0.001
One kind 992 (29.9) 158 (31.4) 755 (29.4) 79 (32.2) <0.001
Two kinds 1135 (34.2) 136 (27.0) 921 (35.9) 78 (31.8) d
Three kinds 586 (17.7) 74 (14.7) 468 (18.2) 44 (18.0) d
More than three kinds 154 (4.6) 19 (3.8) 126 (4.9) 9 (3.7) d
Diuretics 552 (16.6) 109 (21.7) 407 (15.8) 36 (14.7) 0.004
Calcium-channel blocker 1458 (44.0) 250 (49.7) 1092 (42.5) 116 (47.3) 0.007
Beta blocker 1542 (46.5) 116 (23.1) 1323 (51.5) 103 (42.0) <0.001
Angiotensin-converting
enzyme inhibitor
551 (16.6) 30 (6.0) 479 (18.7) 42 (17.1) <0.001
Angiotensin receptor
blocker
1439 (43.4) 215 (42.7) 1129 (44.0) 95 (38.8) 0.279
Alpha blocker 103 (3.1) 10 (2.0) 82 (3.2) 11 (4.5) 0.156
Antidiabetic drugs
Current use 921 (27.8) 102 (20.3) 702 (27.3) 82 (33.5) <0.001
Oral hypoglycemic agents 893 (26.9) 106 (21.1) 710 (27.6) 77 (31.4) 0.003
Insulin 61 (1.8) 4 (0.8) 50 (1.9) 7 (2.9) 0.100
Lipid-lowering drugs
Current use 2420 (73.0) 212 (42.1) 2048 (79.8) 160 (65.3) <0.001
One kind 2208 (66.6) 194 (38.6) 1861 (72.5) 153 (62.4) <0.001
More than one kind 211 (6.4) 18 (3.6) 186 (7.2) 7 (2.9) d
Statins 2285 (68.9) 197 (39.2) 1932 (75.2) 156 (63.7) <0.001
Fibrate 190 (5.7) 21 (4.2) 163 (6.3) 6 (2.4) 0.011
Other lipid-lowering drugs 156 (4.7) 12 (2.4) 139 (5.4) 5 (2.0) 0.002
Antithrombotic drugsa 2759 (85.6) 329 (71.7) 2270 (88.4) 160 (82.1) <0.001
Anticoagulantsa 79 (2.5) 12 (2.6) 62 (2.4) 5 (2.6) 0.963
Antiplateletsa
Current use 2750 (85.4) 329 (71.7) 2262 (88.1) 159 (81.5) <0.001
One kind 2268 (70.4) 295 (64.3) 1849 (72.0) 124 (63.6) <0.001
More than one kind 482 (15.0) 34 (7.4) 413 (16.1) 35 (17.9) d
Aspirin 2168 (67.3) 242 (52.7) 1806 (70.3) 120 (61.5) <0.001
Clopidogrel 715 (22.2) 39 (8.5) 626 (24.4) 50 (25.6) <0.001
Aspirin þ extended release
dipyridamole
89 (2.8) 24 (5.2) 58 (2.3) 7 (3.6) 0.001
Dipyridamole 50 (1.6) 2 (0.4) 45 (1.8) 3 (1.5) 0.110
Ticlopidine 70 (2.2) 28 (6.1) 38 (1.5) 4 (2.1) <0.001
Cilostazol 60 (1.9) 5 (1.1) 51 (2.0) 4 (2.1) 0.416
Values are number (percentage).
CAD Z coronary artery disease; CVD Z cerebrovascular disease.
a 94 patients with a history of hemorrhagic stroke were excluded.
1004 J.-S. Jeng et al.This study also revealed that the target-achieved rates
of BP and lipids, and the frequencies of secondary pre-
vention therapy prescription were significantly lower in
patients with CVD than in those with CAD. Some previous
studies also showed similar findings.11e14 In the World
Health Organization study on the Prevention of Recurrence
of myocardial Infarction and StrokE conducted in several
developing countries, the prescription rate for anti-
platelets, antihypertensives, and statins was lower in pa-
tients with CVD than in those with CAD.11 In the REACH
Registry, CVD patients were less likely to receive antihy-
pertensive drugs and attain good BP control than were CAD
patients.13 In the Vascular Protection and Guideline-
Oriented Approach to Lipid-Lowering registries in Canada,the BP and LDL-C target achievement, and statin and
antihypertensive use were approximately 10% lower in pa-
tients with CVD than in those with CAD.12
The CVDeCAD discrepancy in secondary prevention
therapy of cardiovascular diseases can be explained in
several ways. First, there are disparities of risk perception
between CVD and CAD. Both patients and physicians
regarded CAD as a higher risk than CVD, and the risk-scoring
was lower in patients than in physicians.14 Therefore, the
management of risk factors and target attainment may be
dissimilar. Knowledge of risk factors for stroke and warning
signs of stroke is often suboptimal;26 only 30% of patients
recognized transient ischemic attack and minor stroke
immediately after stroke in a population-based study of
Figure 1 The guideline-recommended BP and LDL target achievement rates by cardiovascular disease category and sex.
BP Z blood pressure; LDL Z low-density lipoprotein; CVD Z cerebrovascular disease; CAD Z coronary artery disease. The BP
target is <140/90 mmHg for nondiabetic patients and <130/80 mmHg for diabetic patients; and the LDL target is LDL cholesterol
<2.6 mmol/L (100 mg/dL).
Guideline-adherent therapy in cardiovascular diseases 1005behavior.27 Second, stroke comprises heterogeneous etiol-
ogies, and the approach to management may be differen-
tial depending on the etiology. Statins, for example, are
recommended for use in patients with atherosclerotic
ischemic stroke or transient ischemic attack,20 but it is
arguable whether statins should be routinely used in everyTable 3 Multivariate logistic regression analysis of variables as
LDL target
OR (95% CI) p O
Age
<65 y 1.00 d 1
65e74 y 1.30 (1.10e1.55) 0.002 0
75 y 1.31 (1.09e1.55) 0.003 0
Women 0.72 (0.61e0.85) <0.001 0
Diabetes mellitus 1.36 (1.17e1.57) <0.001 0
Statin use 1.58 (1.34e1.87) <0.001 d
Fibrate use 0.90 (0.66e1.22) 0.483 d
Antihypertensive drugs use
(more than three kinds)
d d 0
Cardiovascular disease
category
CAD only 1.00 d 1
CVD only 0.67 (0.55e0.83) <0.001 0
CAD and CVD 0.84 (0.64e1.10) 0.212 0
The BP target is <140/90 mmHg for nondiabetic patients and <130/80
<2.6 mmol/L (100 mg/dL).
BP Z blood pressure; CAD Z coronary artery disease; CI Z confiden
lipoprotein; OR Z odds ratio.CVD patient, including nonatherosclerotic diseases such as
dissection of small artery lacune.28 Third, the choice of
antihypertensive agents in CAD patients should not depend
only on BP status. According to the American Heart Asso-
ciation guideline, patients with coronary and other
atherosclerotic vascular disease who have BP >140/sociated with lipid and BP targets achievement.
BP target LDL and BP targets
R (95% CI) p OR (95% CI) p
.00 d 1.00 d
.93 (0.79e1.11) 0.428 1.13 (0.94e1.35) 0.194
.91 (0.76e1.09) 0.289 1.20 (0.99e1.45) 0.062
.72 (0.62e0.85) <0.001 0.65 (0.55e0.78) <0.001
.38 (0.33e0.43) <0.001 0.60 (0.52e0.71) <0.001
d 1.37 (1.14e1.65) 0.001
d 0.80 (0.57e1.14) 0.223
.74 (0.62e0.88) <0.001 0.80 (0.73e1.05) 0.158
.00 d 1.00 d
.78 (0.64e0.95) 0.015 0.61 (0.48e0.78) <0.001
.71 (0.54e0.93) 0.014 0.70 (0.52e0.96) 0.025
mmHg for diabetic patients; and the LDL target is LDL cholesterol
ce intervals; CVD Z cerebrovascular disease; LDL Z low-density
1006 J.-S. Jeng et al.90 mmHg should be treated initially with b-blockers and/or
angiotensin-converting enzyme inhibitors; and patients
with heart failure should consider the use of b-blockers,
angiotensin-converting enzyme inhibitors, and/or angio-
tensin receptor blockers.4 However, in guidelines for stroke
prevention, the optimal antihypertensive drug regimen to
achieve the recommended level of BP reduction is uncer-
tain.20 As a result, our study also showed b-blockers and
angiotensin-converting enzyme inhibitors were more likely
to be prescribed in patients with CAD than in those with
CVD.
The present study showed a sex difference of target
achievement. Women with CVD and/or CAD were less likely
to receive secondary prevention therapies, and reach the
guideline-recommended targets. Previous studies have also
demonstrated that women were less likely to receive sec-
ondary prevention therapies.16,17 According to the Get With
The Guidelines-Stroke, the quality of care for women with
acute ischemic stroke was lower than that for men.29 Sex
difference of the medication may be explained by older
age, greater comorbidity, and higher stroke severity in
women.30 Elderly CVD patients were substantially less likely
to receive secondary prevention after a stroke, especially
the lipid-lowering drugs.23
This study has several limitations. First, this study’s
patients were recruited mainly from the departments of
cardiology and neurology of the teaching hospitals, unlike
the case in some studies where the patient source was
mainly from the general practitioners. Although the results
from this study may have the problem of generalizability
of our results, in Taiwan there was little restriction of
patients’ assessment to hospitals, and patients often
continued their outpatient clinics management at the
same hospitals where they were hospitalized for the major
diseases. Second, it is likely that patients with severe
stroke with ambulation difficulty may have restricted their
presentation to an outpatient clinic and hence to inclusion
in the study. It is possible that an overestimation of
medication use in CVD patients occurred in this study. The
disparity of medication between CAD and CVD patients
may be even wider than shown here. Third, we had no
detailed information about patients’ compliance and
duration of secondary prevention therapies, contraindi-
cation or reasons for discontinuing some medications, and
lifestyle modifications. The information about each
participant was obtained from direct medical records and
interviewing, and will be followed up periodically. The
validity of these data is high. Fourth, there were dispro-
portionately fewer CVD patients than CAD patients in this
study, as compared with the real-world prevalence of CVD
and CAD in Taiwan population, owing to cardiologists
comprising the majority of the T-SPARCLE Registry in-
vestigators. It is mandatory to recruit more CVD patients in
this ongoing registry for better representation of cardio-
vascular diseases in Taiwan.
In conclusion, the guideline-recommended medication
and target achievement among patients with cardiovas-
cular diseases are still suboptimal. Greater efforts are
required to direct health-care professionals and patient
education, and awareness and adherence to guidelines,
particularly in patients with CVD and in women.Acknowledgments
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